Research Article

The Safety and Feasibility of Laparoscopic Gastrectomy after Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

Table 1

Baseline, demographics, and clinical features of cases in this study.

Demographics and clinical featuresLAGOG value
N = 77 (%)N = 76 (%)

Age (years)60.4 ± 9.459.3 ± 10.60.675
Gender0.295
 Male53 (66.8)59 (77.6)
 Female24 (31.2)17 (22.4)
BMI (kg/m2)23.0 ± 3.223.7 ± 2.90.188
Hemoglobin (g/L)123.9 ± 17.3120.9 ± 21.40.487
Albumin (g/L)42.3 ± 2.942.0 ± 3.20.434
Tumor size3.6 ± 1.74.5 ± 2.60.038
Longitudinal location0.329
Esophagogastric junction17 (22.1)25 (32.9)
 Fundus14 (18.2)16 (21.1)
 Corpus17 (22.1)12 (15.8)
 Antrum29 (37.7)22 (28.9)
 The whole stomach0 (0)1 (1.3)
Borrmann type0.233
 Type 02 (2.6)2 (2.6)
 Type I0 (0)4 (5.3)
 Type II21 (27.3)14 (18.4)
 Type III48 (63.2)48 (63.2)
 Type IV6 (7.8)8 (10.5)
ycT stage0.722
 T27 (9.1)7 (9.2)
 T323 (29.9)17 (22.4)
 T4a42 (54.5)45 (59.2)
 T4b5 (6.5)7 (9.2)
ycN stage0.955
 N07 (9.1)7 (9.2)
 N135 (45.5)32 (42.1)
 N226 (33.8)26 (34.2)
 N39 (11.7)11 (14.5)
ycTNM stage0.939
 IIA7 (9.1)7 (9.2)
 IIB7 (9.1)7 (9.2)
 III58 (75.3)55 (72.4)
 IVA5 (6.5)7 (9.2)

BMI : body mass index; the yc stages were indicated by preoperative CT scan after neoadjuvant chemotherapy, and all staging was based on the eighth edition of the AJCC Cancer Staging Manual by the American Joint Committee on Cancer and International Union Against Cancer.